# A Study of Oraxol® in Gastric Cancer Patients

> **NCT01491217** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 53 (estimated)

## Conditions studied

- Advanced Metastatic Gastric Cancer
- Recurrent Gastric Cancer

## Interventions

- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01491217
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-05
- **Primary completion:** 2012-03
- **Final completion:** 2012-12
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2011-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491217, "A Study of Oraxol® in Gastric Cancer Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01491217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*